Navigation Links
Resisting lung cancer recurrence
Date:2/4/2008

(New York, February 5th) -- What if we could prevent cancer recurrence for years after surgery by giving simple recall injections every two or three years" This concept may no longer be a fantasy. In a clinical study published online this week by the Proceedings of the National Academy of Sciences USA, a team headed by the international Ludwig Institute for Cancer Research (LICR) has shown that a vaccine against a protein found in cancer cells produces an immune response that can be boosted and strengthened with additional vaccine shots. Patients with resected non-small cell lung cancer (NSCLC) were treated with this investigational agent, also known as an Antigen-Specific Cancer Immunotherapeutic (ASCI), in another clinical study conducted by GlaxoSmithKline. The results showed a reduction in risk of cancer recurrence in these patients, a finding that prompted GlaxoSmithKline to initiate the largest ever clinical trial in lung cancer (MAGRIT study).

According to LICRs Dr. Sacha Gnjatic, the senior author of this LICR-sponsored study, the long immunological memory is exactly what cancer immunologists are hoping to see. Vaccines against infectious diseases induce immunological responses that typically last for years, and ideally we want a cancer vaccine that does the same thing. We previously learned that our vaccine could stimulate an immune response recognizing a protein found in lung cancer cells but we did not know how long the response lasted. We now know that this vaccine induces strong and persistent immunity over several years, which can be further boosted with additional vaccination. Dr. Gnjatic said that the booster shots, given two years after the first cycle of vaccinations, not only reactivated the initial immune response in patients who received the priming vaccination, it also diversified the types of immune cells specific for the cancer protein. Weve not only kept the immune system interested, weve also got it to more broadly recognize the protein that marks the cell as being a cancer cell.

LICR and the Cancer Research Institute, both head-quartered in New York, supported the study under the auspices of the Cancer Vaccine Collaborative, with the clinical component conducted by Dr. Nasser Altorki at New York Presbyterian Hospital / Weill Medical College of Cornell University.

Cancer vaccines have two principal components. One component, the adjuvant, stimulates the immune system in a general way, and the other component, the tumor antigen in this case, the MAGE-A3 antigen directs the immune response specifically against the cancer cell. Last month, another LICR-sponsored clinical trial within the Cancer Vaccine Collaborative showed that a cancer vaccine based on the tumor antigen NY-ESO-1 stimulated an immune response in women with ovarian cancer. The results from that trial were suggestive that a similar boost strategy could be beneficial for long-term immunological memory in that disease also.

A completely unexpected finding from the present study was that the inital formulation and delivery of the tumor antigen to the immune system is critical and suggests that the combination of the antigen with an immunological adjuvant is key. The original, small clinical study, conducted three years ago by the Cancer Vaccine Collaborative, showed that the adjuvant was necessary for activation of the immune system; patients who received antigen alone failed to mount specific immune responses. Surprisingly, these same patients also failed to mount immune responses even when they received the full vaccine adjuvant plus antigen as a booster shot.

This is such a surprising result, says LICRs Dr. Lloyd Old, another author on the study and Director of the Cancer Vaccine Collaborative. In the vaccine field, boosters are given to convert negative or weak reactions to positive ones, and we really thought we would see the same thing. One intriguing possibility is that regulatory mechanisms were activated following the original weak response induced by the vaccine without adjuvant. These findings will certainly have ramifications for the whole field to determine the formulation and delivery of future cancer vaccines.


'/>"/>

Contact: Sarah L. White, Ph.D.
swhite@licr.org
917-379-0398
Ludwig Institute for Cancer Research
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... When it came time to blow out his candles on ... later, the Pediatric Heart Transplant team at Joe DiMaggio Children’s Hospital surprised his ... the hospital’s 30th heart transplant recipient. , “He was playing at home, when we ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... financial consultation services to residents in the Sacramento/Folsom region, is initiating a charity ... facility. , The Another Choice Another Chance treatment center in Sacramento works to ...
(Date:12/7/2016)... , ... December 07, 2016 , ... AlignLife clinics nationwide ... Many children are not fortunate enough to receive bountiful gifts wrapped tightly under a ... can bring to the children of the world. , In exchange for generous donations, ...
(Date:12/7/2016)... OR (PRWEB) , ... December 07, 2016 , ... Sharon ... Water, Global Climate Change and Your Health on Voice of America, declared on her ... to call attention to the fact that when these bullies attack leaders in corporate ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... Research and Markets has announced the addition of the ... to 2021" report to their offering. ... , , The immunohistochemistry (IHC) ... a CAGR of 7.3% during the forecast period of 2016 to 2021. ... rapidly increasing geriatric population across the globe are the primary driving the ...
(Date:12/7/2016)... 7, 2016  Palatin Technologies, Inc. ("Palatin") (NYSE ... a previously disclosed underwritten public offering of units ... as sole book-running manager, Roth Capital Partners acted ... as co-manager for the offering. "This ... net proceeds, allowing us to continue advancing bremelanotide ...
(Date:12/7/2016)... , Dec. 7, 2016 DelveInsight,s, ... report provides in depth insights on the ... the Janus Kinase 3 (JAK3) Inhibitors. The ... various stages of development including Discovery, Pre-clinical, ... and Preregistration. Report covers the product clinical ...
Breaking Medicine Technology: